Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165769 | 0.98 | KMT2A (0.54) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL12014424 | 0.87 | KMT2A (0.46) | KMT2AMEN1 | |
| SCHEMBL12014419 | 0.86 | KMT2A (0.49) | KMT2AMEN1HPGD | |
| SCHEMBL3294445 | 0.85 | THRB (0.50) | KMT2AMEN1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL16829927 | 0.85 | CYP2D6 (0.57) | ALDH1A1POLBMAPTCYP1A2HRH3 | |
| SCHEMBL2254970 | 0.84 | KMT2A (0.50) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL12014431 | 0.82 | KMT2A (0.43) | KMT2AMEN1HPGDBCHESIGMAR1 | |
| SCHEMBL165770 | 0.82 | KMT2A (0.53) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL65995 | 0.82 | SLC18A3 (0.53) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL11593239 | 0.82 | SIGMAR1 (0.50) | KMT2AMEN1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-02-09 | — | — | US | claimed |
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-11-12 | — | — | US | claimed |
| EP-3453714-B1 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | SUZHOU NEUPHARMA CO LTD (CN) | 2020-11-04 | — | — | EP | claimed |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-08 | — | — | US | claimed |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | claimed |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-01-23 | — | — | US | claimed |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2019-07-09 | — | — | US | claimed |
| EP-3453714-A2 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | Suzhou Neupharma Co., Ltd (CN) | 2019-03-13 | — | — | EP | claimed |
| US-20170088580-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-03-30 | — | — | US | claimed |
| US-9018197-B2 | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use | SUZHOU NEUPHARMA CO. LTD. (CN) | 2015-04-28 | — | — | US | claimed |
| CN-102203112-B | Certain compounds, compositions and methods | SUZHOU NEUPHARMA CO LTD | 2014-05-07 | — | — | CN | claimed |
| CN-103619865-A | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO LTD | 2014-03-05 | — | — | CN | claimed |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2012-08-02 | — | — | US | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240115585-A1 | METHODS OF TREATING CANCER | NEUPHARMA, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-2523966-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Suzhou Neupharma Co., Ltd (CN) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | disclosed |
| US-20110201584-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | KMT2A 2329/4885MEN1 22/4885ALDH1A1 290/4885 |
| US-20170088580-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | KMT2A 2329/4885MEN1 22/4885ALDH1A1 290/4885 |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | UGT2B7, BCCIP, ABCG2 | KMT2A 3692/4885MEN1 281/4885ALDH1A1 422/4885 |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | KMT2A 2329/4885MEN1 22/4885ALDH1A1 290/4885 |
| US-20240115585-A1 | METHODS OF TREATING CANCER | TP53, DDX21, BRCA1 | KMT2A 2026/4885MEN1 957/4885ALDH1A1 280/4885 |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | KMT2A 2329/4885MEN1 22/4885ALDH1A1 290/4885 |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | KMT2A 2329/4885MEN1 22/4885ALDH1A1 290/4885 |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | KMT2A 3692/4885MEN1 281/4885ALDH1A1 422/4885 |
| US-20110201584-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | KMT2A 3692/4885MEN1 281/4885ALDH1A1 422/4885 |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | KMT2A 2329/4885MEN1 22/4885ALDH1A1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.